Breast cancer is complex.
Understanding your treatment options shouldn’t be.
After getting my BCI™ [Breast Cancer Index®] Results, if I could sum up that feeling in one word, I would say relief. Relief that I don't have to take this [medication] daily anymore."
Women like Cheryl found their finish to anti-estrogen therapy. Let stories like hers help you find yours.
Women like Cheryl found their finish to anti-estrogen therapy. Let stories like hers help you find yours.
Frequently Asked Questions
While other tests provide information about your risk of recurrence, only the BCI Test is validated and recognized by national oncology guidelines to provide your personal risk of recurrence and determine whether continuing anti-estrogen therapy beyond 5 years is likely to help reduce that risk.1-7
Both the Oncotype DX and BCI Tests are genomic assays to help with breast cancer treatment decisions by predicting therapy benefit, however, they are used to inform different treatment decisions.
Oncotype DX predicts whether you are likely to benefit from chemotherapy and provides your overall risk of a metastatic recurrence within the first 9 years since diagnosis for node-negative patients or the first 5 years since diagnosis for node-positive patients.8
On the other hand, the BCI Test provides unique information to help providers and patients make a decision around the length of anti-estrogen therapy (5 vs. 10 years) by predicting whether you are likely to benefit from continuing anti-estrogen therapy after the 5-year mark and your specific risk of metastatic recurrence in years 5-10, with or without longer treatment.9
You may be eligible for BCI Testing if:
- You are biologically female and have been diagnosed with early-stage (I to IIIa) breast cancer.
- You are node-negative or node-positive with up to 3 positive nodes.
- Your breast cancer is estrogen receptor–positive (ER+) and/or progesterone receptor-positive (PR+).
- You have been prescribed anti-estrogen (also called hormonal or endocrine) therapy.
- You are breast cancer-free.
Download the Conversation Guide to ask your doctor if the BCI Test is right for you.
Breast Cancer Index Testing does not require any additional procedures. After your doctor orders the BCI Test, Biotheranostics reaches out to the pathology lab to collect the tumor sample from your original biopsy or surgery.
BCI Testing is typically ordered around the 4-year mark as you prepare to make a decision about whether to continue anti-estrogen therapy beyond year 5. If you are already past the 5-year mark, you may still be eligible for the test. Start the conversation early and talk to your doctor about when ordering the test is right for you!
The time it takes to run BCI Testing from the initial order can vary based on a variety of factors, including patient and client services outreach, order processing, verification of your eligibility for testing, and the time it takes to receive your original tumor sample from the pathology lab. Once the specimen and all required information have been received, testing typically takes 7-10 business days.
The Breast Cancer Index Test is covered by Medicare with no copay or deductible when criteria are met under the Local Coverage Determination: CMS.gov. Contact our Patient Services Team with specific questions.
For non-Medicare patients, your commercial insurance may also cover the test. As with all health-related visits, tests, or procedures, you should be aware of your deductible, co-pay, and co-insurance responsibilities. If your out-of-pocket cost is expected to be more than $100, a member of our patient services team will contact you after an order is placed to discuss the billing process and our financial assistance program.
If you are interested in getting an estimate on cost before an order is placed, you may contact our Patient Services Team directly at Patient.Services@hologic.com or (844) 319-8111.
Your test results will be sent back to your healthcare provider who ordered the test. They will review your results with you and discuss treatment recommendations.
Testing must be ordered by a provider with a valid National Provider ID (NPI) within the United States. International patients may find a U.S.-based provider to order the test. International patients are responsible for retrieval and shipping of the specimen. This includes shipping cost and ensuring the specimen is properly preserved for shipping.
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 28, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F, et al. J Clin Oncol. 2022;40(16):1816-1837. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org]. ASCO makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way. 3. Zhang Y, et al. Clin Cancer Res. 2013;19(15):4196-4205. 4. Sgroi DC, et al. J Natl Cancer Inst. 2013;105(14):1036-1042. 5. Bartlett JMS, et al. Clin Cancer Res. 2022;28(9):1871-1880. 6. Noordhoek I, et al. Clin Cancer Res. 2021;27(17):311-319. 7. Mamounas EP, et al. Clin Cancer Res. 2024;30(9):1984-1991. 8. www.precisiononcology.exactsciences.com. 9. www.breastcancerindex.com.